About
Kheiron Medical Technologies was founded in 2016 in London, UK, with a mission to leverage deep learning and data science to help radiologists detect breast cancer earlier and more accurately. Its flagship product, Mia™ (Mammography Intelligent Assessment), is a CE-marked AI solution that integrates seamlessly into existing breast cancer diagnostic workflows. Mia™ offers three distinct operating modes: as an independent reader replacing a second human radiologist, as a concurrent reader providing real-time AI-assisted decision support, and as a triage tool prioritizing cases by urgency to optimize workflow efficiency. The platform was designed to reduce missed cancers, lower unnecessary recalls, and ease the burden on radiologists in high-volume screening environments. In 2020, Kheiron won the prestigious AI in Health and Care Award, recognizing the clinical impact of its technology. In 2024, Kheiron was acquired by DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. Under DeepHealth, Kheiron's capabilities have evolved into SmartMammo™, an enterprise-grade AI breast screening solution. The broader DeepHealth platform extends AI-powered diagnostics into prostate, chest, neuro, and thyroid imaging, serving large-scale population health and screening programs worldwide.
Key Features
- Mia™ Independent Reader: AI acts as a fully independent second reader in breast screening workflows, reducing the need for a second human radiologist without sacrificing diagnostic accuracy.
- Concurrent AI Decision Support: Provides real-time AI-generated insights alongside the radiologist during image review, improving confidence and reducing missed cancers.
- Intelligent Triage Tool: Automatically prioritizes mammography cases by clinical urgency, helping radiology teams manage high-volume screening programs more efficiently.
- CE-Marked Medical AI: Mia™ received CE marking in Europe in 2019, meeting rigorous medical device regulatory requirements for clinical deployment.
- Enterprise Workflow Integration: Designed for seamless integration into existing PACS, RIS, and diagnostic imaging environments with minimal disruption to established clinical workflows.
Use Cases
- National and regional breast cancer screening programs seeking AI to augment or replace second-reader workflows
- Radiology departments using AI triage to prioritize high-risk mammography cases and reduce reporting backlogs
- Hospitals integrating concurrent AI reading to improve diagnostic accuracy and reduce radiologist cognitive load
- Healthcare providers validating AI-assisted screening against peer-reviewed clinical evidence before deployment
- Enterprise imaging networks looking to unify diagnostic AI across breast, prostate, chest, and neuro modalities under one platform
Pros
- Clinically Validated & Certified: Mia™ is CE-marked and backed by peer-reviewed scientific publications, giving healthcare institutions confidence in its safety and efficacy.
- Flexible Deployment Modes: Supports independent reading, concurrent reading, and triage — allowing institutions to choose the integration model that best fits their workflow.
- Enterprise-Grade Backing: Now part of DeepHealth/RadNet, users benefit from a well-resourced ecosystem covering multiple imaging modalities beyond breast screening.
- Award-Winning Technology: Winner of the UK AI in Health and Care Award in 2020, recognizing measurable real-world clinical impact.
Cons
- Original Brand Sunset: Kheiron's identity and standalone Mia™ product have been folded into DeepHealth's SmartMammo™, which may require existing users to transition platforms.
- Enterprise-Only Pricing: Designed for hospitals and large screening programs, making it inaccessible to independent radiologists or smaller clinics without institutional agreements.
- Primarily Breast Screening Focused: The original Kheiron platform was purpose-built for mammography, limiting its direct applicability to other imaging specialties without adopting the broader DeepHealth suite.
Frequently Asked Questions
What is Mia™?
Mia™ (Mammography Intelligent Assessment) is Kheiron's AI-powered breast cancer screening solution. It uses deep learning to analyze mammography images and can serve as an independent reader, a concurrent reader alongside radiologists, or a triage tool to prioritize cases.
Is Kheiron Medical still operating independently?
No. In 2024, Kheiron Medical Technologies was acquired by DeepHealth, a subsidiary of RadNet, Inc. The Mia™ technology has been evolved into SmartMammo™ under the DeepHealth brand.
Is Mia™ approved for clinical use?
Yes. Mia™ received CE marking in Europe in 2019, certifying it as a medical device compliant with European regulatory standards for clinical deployment in breast cancer screening.
How does Kheiron's AI integrate with existing hospital systems?
Kheiron's solutions were designed for seamless integration into existing PACS and RIS environments, fitting into established radiology workflows without requiring significant infrastructure changes.
Who is the target customer for Kheiron / DeepHealth's breast screening AI?
The primary customers are large healthcare institutions, national breast screening programs, hospital networks, and radiology departments running high-volume mammography workflows.
